Kazia Therapeutics share price logo

Kazia Therapeutics

NASDAQ: KZIA

$14.43

+0.87

(+6.42%)

as on

Kazia Therapeutics Stock Performance

as on August 19, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $13.00
    $14.72
    downward going graph

    9.91%

    Downside

    2.01%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $4.86
    $17.40
    downward going graph

    66.32%

    Downside

    20.58%

    Upside

    downward going graph

Kazia Therapeutics share price movements today

Previous Close
$13.56
Open
$13.37
Volume
393.7K
Market Cap
$154.5M
Day's Low - High
$13.00 - $14.72
52 Week Low - High
$4.86 - $17.40

Kazia Therapeutics Historical Returns

1 Month Return
+ 1.35 %
3 Month Return
+ 2.74 %
1 Year Return
+ 68.26 %
3 Year Return
-69.96 %
5 Year Return
-96.94 %

Kazia Therapeutics Stock Fundamentals & Key Indicators

Check Kazia Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$154.5M

EPS (TTM)

-10.35

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-1.81

Industry PE ratio

-3.712675585284281

PEG Ratio

-0.018901504571297956

EBITDA

-18.2M

Revenue (TTM)

19.7K

Profit Margin

100.00%

Return On Equity TTM

-116.86%

Kazia Therapeutics Stock Valuation

Track how Kazia Therapeutics P/E has moved over time to understand its valuation trends.

Kazia Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-18.37x)

June 30, 2021

Industry (-3.71x)

June 30, 2025

Today (-0.50x)

June 30, 2025

Highest (-0.29x)

June 30, 2024

LowHigh

Today’s Price to Earnings Ratio: -0.50x

Kazia Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Kazia Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Kazia Therapeutics image
Kazia Therapeutics
BUY$154.5M-96.94%-1.81100.00%NA
Revolution Medicines image
Revolution Medicines
BUY$43.7B669.3%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$128.2B154.86%29.8286.04%NA
Regeneron image
Regeneron
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for Kazia Therapeutics Stock including INR - Dollar returns

The Kazia Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Kazia Therapeutics investment value today

Current value as on today

₹1,96,783

Returns

₹96,783

(+96.78%)

Returns from Kazia Therapeutics Stock

₹79,589 (+79.59%)

Dollar Impact

₹17,194 (+17.19%)

Analyst Recommendation on Kazia Therapeutics Stock

Based on 5 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 5 analysts, 100% of analysts recommend a 'BUY' rating for Kazia Therapeutics. Average target price of $28.2

Kazia Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Kazia Therapeutics.

What analysts predicted

48.83%UPSIDE

Target Price

$28.2

Current Price

$14.43

Analyzed by

5 Analysts

Target

$28.20

Kazia Therapeutics target price $28.2, a slight upside of 48.83% compared to current price of $14.43. According to 5 analysts rating.

Indian Investors' Interest in Kazia Therapeutics Stock

Search interest for Kazia Therapeutics Stock has increased by 18% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:18% versus previous 30 day period

Kazia Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Jun 2021
Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Jun 2024
Dec 2024
Jun 2025
Dec 2025
Total Revenue
15
0
-
-
0
0
2
0
0
-
Gross Profit
15
0
0
0
0
0
2
0
0
-
Operating Income
0
-13
-25
-13
-10
-8
-19
-9
-4
-13
EBITDA
0
-12
-11
-12
-9
-7
-18
-8
-4
-13
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
-
-
Income Before Tax
-2
-13
-11
-13
-7
-8
-18
-10
-11
-12
Income Tax Expense
0
0
0
0
0
0
0
0
-1
-
Net Income
-2
-13
-11
-13
-6
-8
-17
-10
-9
-12
Net Profit Margin
100.00%
100.00%
0.00%
0.00%
100.00%
100.00%
100.00%
100.00%
100.00%
0.00%

Kazia Therapeutics Annual Profit & Loss

All numbers in Millions USD

Jun 2017
Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Jun 2023
Jun 2024
Jun 2025
Total Revenue
8
0
0
0
15
0
0
2
0
Gross Profit
8
0
0
0
15
0
0
2
0
Operating Income
-10
-12
-8
-12
-6
-25
-24
-28
-14
EBITDA
-9
-10
-7
-11
-5
-23
-22
-26
-13
Interest Expense
-
-
2
-
-
0
-
-
-
Depreciation
1
1
1
1
1
1
1
1
0
Income Before Tax
-10
-6
-10
-12
-8
-25
-20
-27
-22
Income Tax Expense
0
0
0
0
0
0
0
0
-1
Net Income
-10
-6
-10
-12
-8
-25
-20
-26
-20
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%

Kazia Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2021
Dec 2021
Jun 2022
Dec 2022
Jun 2023
Dec 2023
Jun 2024
Dec 2024
Jun 2025
Dec 2025
Net Income
-2
-13
-11
-13
-6
-8
-17
-5
-9
-12
Operating Cash Flow
3
-11
-11
-8
-6
-6
-3
-4
-4
-9
Investing Cash Flow
23
0
0
7
-5
5
-
-
-
-
Financing Cash Flow
4
0
3
5
7
4
0
4
5
73
Change in Cash
8
-4
-19
4
-3
3
-1
0
1
65

Kazia Therapeutics Annual Cash Flow

All numbers in Millions USD

Jun 2017
Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Jun 2023
Jun 2024
Jun 2025
Net Income
-10
-6
-10
-12
-8
-25
-20
-26
-20
Operating Cash Flow
-11
-8
-6
-8
-9
-22
-15
-9
-13
Investing Cash Flow
-7
0
2
-
-
-2
-
-
-
Financing Cash Flow
0
-
3
12
28
3
12
5
15
Change in Cash
-18
-8
0
3
18
-20
-2
-3
2

Mutual Funds that own Kazia Therapeutics Stock

Check out the Mutual Funds with significant holdings in Kazia Therapeutics.

Funds
Holdings
Shares Held
Fidelity Concord Street Trust
0.001715%
196

Global Institutional Holdings in Kazia Therapeutics

Funds
Holdings
ActivePassive
0.03%

Insights on Kazia Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, KZIA stock has moved up by 134.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 615.7% return, outperforming this stock by 685.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 481.6% return, outperforming this stock by 398.9%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -9.95M → -12.32M (in $), with an average decrease of 23.8% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 2.48M → 19.71K (in $), with an average decrease of 55.3% per quarter

About Kazia Therapeutics

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
OrganisationKazia Therapeutics
HeadquartersThree International Towers, Sydney, NSW, Australia, 2000
IndustryBiotechnology
CEODr. John Edwin Friend II, M.D.
E-voting on sharesClick here to vote

Key Management of Kazia Therapeutics

Name

Title

Dr. Sudha Rao

Chief Scientific Officer

Dr. John Edwin Friend II, M.D.

Chief Executive Officer

Ms. Elissa C. Hansen ACSA, B.Com., B.Comm, FCIS, Gad Dip ACG, GAI, GAIC

Company Secretary

Mr. Jeffrey Bonacorda

VP of Finance & Controller

Mr. James E. Levine

Chief Financial Officer

FAQs

What is Kazia Therapeutics share price today?

Kazia Therapeutics share price today is $14.43 as on at the close of the market. Kazia Therapeutics share today touched a day high of $14.72 and a low of $13.00.

What is the 52 week high and 52 week low for Kazia Therapeutics share?

Kazia Therapeutics share touched a 52 week high of $17.40 on and a 52 week low of $4.86 on . Kazia Therapeutics stock price today i.e. is closed at $14.43,which is 17.07% down from its 52 week high and 196.91% up from its 52 week low.

What is Kazia Therapeutics's market capitalisation today?

Kazia Therapeutics market capitalisation is $0.00T as on .

How to invest in Kazia Therapeutics Stock (KZIA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Kazia Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Kazia Therapeutics Shares that will get you 0.1040 shares as per Kazia Therapeutics share price of $14.43 per share as on August 19, 2026 at 1:29 am IST.

What is the minimum amount required to buy Kazia Therapeutics Stock (KZIA) from India?

Indian investors can start investing in Kazia Therapeutics (KZIA) shares with as little as ₹95.67 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹956.70 in Kazia Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Kazia Therapeutics share’s latest price of $14.43 as on August 19, 2026 at 1:29 am IST, you will get 0.6930 shares of Kazia Therapeutics. Learn more about fractional shares .

What are the returns that Kazia Therapeutics has given to Indian investors in the last 5 years?

Kazia Therapeutics stock has given -96.94% share price returns and 28.7% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?